Eupraxia Pharmaceuticals (EPRX) Research & Development (2023 - 2026)
Eupraxia Pharmaceuticals (EPRX) posted quarterly Research & Development of $11.2 million for Q1 2026, up 190.25% year-over-year from $3.8 million in Q1 2025, and up 42.03% quarter-over-quarter from $7.9 million in Q4 2025.
Eupraxia Pharmaceuticals (EPRX) Research & Development (2023 - 2026) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has reported Research & Development for 4 consecutive years, with $11.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 190.25% year-over-year to $11.2 million; the TTM figure through Mar 2026 stood at $28.7 million (up 78.57% YoY), while the FY2025 annual figure was $21.3 million, up 32.67% from the prior year.
- Research & Development climbed to $11.2 million in Q1 2026 per EPRX's latest filing, from $7.9 million in the prior quarter.
- Across five years, Research & Development topped out at $11.2 million in Q1 2026 and bottomed at $2.3 million in Q1 2023.
- Historically, Research & Development has averaged $5.6 million across 4 years, with a median of $4.4 million in 2025.
- Annual changes were most pronounced in 2024 — Research & Development tumbled 58.38% — and 2026, when it surged 190.25%.
- Eupraxia Pharmaceuticals' Research & Development stood at $9.5 million in 2023, then sank by 58.38% to $4.0 million in 2024, then surged by 98.08% to $7.9 million in 2025, then soared by 42.03% to $11.2 million in 2026.
- Business Quant data shows EPRX's Research & Development at $11.2 million in Q1 2026, $7.9 million in Q4 2025, and $4.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Eupraxia Pharmaceuticals | 381.11 Mn | 379.51 Mn | - | 11.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.17 Mn |
| Dec 31, 2025 | 7.87 Mn |
| Sep 30, 2025 | 4.42 Mn |
| Jun 30, 2025 | 5.20 Mn |
| Mar 31, 2025 | 3.85 Mn |
| Dec 31, 2024 | 3.97 Mn |
| Sep 30, 2024 | 4.05 Mn |
| Mar 31, 2024 | 4.18 Mn |
| Dec 31, 2023 | 9.54 Mn |
| Sep 30, 2023 | 4.76 Mn |
| Mar 31, 2023 | 2.27 Mn |